Ji‐Youn Han

24.8k total citations · 8 hit papers
257 papers, 13.1k citations indexed

About

Ji‐Youn Han is a scholar working on Pulmonary and Respiratory Medicine, Oncology and Molecular Biology. According to data from OpenAlex, Ji‐Youn Han has authored 257 papers receiving a total of 13.1k indexed citations (citations by other indexed papers that have themselves been cited), including 194 papers in Pulmonary and Respiratory Medicine, 171 papers in Oncology and 66 papers in Molecular Biology. Recurrent topics in Ji‐Youn Han's work include Lung Cancer Treatments and Mutations (182 papers), Lung Cancer Research Studies (75 papers) and Lung Cancer Diagnosis and Treatment (56 papers). Ji‐Youn Han is often cited by papers focused on Lung Cancer Treatments and Mutations (182 papers), Lung Cancer Research Studies (75 papers) and Lung Cancer Diagnosis and Treatment (56 papers). Ji‐Youn Han collaborates with scholars based in South Korea, United States and United Kingdom. Ji‐Youn Han's co-authors include Myung‐Ju Ahn, Margarita Majem, Dong‐Wan Kim, Edward B. Garon, Roy S. Herbst, Paul Baas, José Luis Perez‐Gracia, Joo-Hang Kim, Gregory M. Lubiniecki and Enriqueta Felip and has published in prestigious journals such as The Lancet, Nature Communications and Journal of Clinical Oncology.

In The Last Decade

Ji‐Youn Han

248 papers receiving 13.0k citations

Hit Papers

Pembrolizumab versus docetaxel for previously treated, PD... 2012 2026 2016 2021 2015 2012 2016 2018 2020 1000 2.0k 3.0k 4.0k
What are hit papers?

Hit papers significantly outperform the citation benchmark for their cohort. A paper qualifies if it has ≥500 total citations, achieves ≥1.5× the top-1% citation threshold for papers in the same subfield and year (this is the minimum needed to enter the top 1%, not the average within it), or reaches the top citation threshold in at least one of its specific research topics.

  1. Pembrolizumab versus docetaxel for previously treated, PD-L1-positive, advanced non-small-cell lung cancer (KEYNOTE-010): a randomised controlled trial
    2015 4.9k citations Ji‐Youn Han, Joo-Hang Kim et al. profile →
  2. First-SIGNAL: First-Line Single-Agent Iressa Versus Gemcitabine and Cisplatin Trial in Never-Smokers With Adenocarcinoma of the Lung
    2012 611 citations Ji‐Youn Han, Sang‐We Kim et al. Journal of Clinical Oncology profile →
  3. Osimertinib for pretreated EGFR Thr790Met-positive advanced non-small-cell lung cancer (AURA2): a multicentre, open-label, single-arm, phase 2 study
    2016 502 citations Jong Seok Lee, Ji‐Youn Han et al. profile →
  4. CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3)
    2018 349 citations Yi‐Long Wu, Myung‐Ju Ahn et al. Journal of Clinical Oncology profile →
  5. Osimertinib plus savolitinib in patients with EGFR mutation-positive, MET-amplified, non-small-cell lung cancer after progression on EGFR tyrosine kinase inhibitors: interim results from a multicentre, open-label, phase 1b study
    2020 295 citations Lecia V. Sequist, Ji‐Youn Han et al. profile →
  6. Five Year Survival Update From KEYNOTE-010: Pembrolizumab Versus Docetaxel for Previously Treated, Programmed Death-Ligand 1–Positive Advanced NSCLC
    2021 201 citations Edward B. Garon, Dong‐Wan Kim et al. profile →
  7. Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON
    2022 95 citations Ryan J. Hartmaier, Aleksandra Markovets et al. Cancer Discovery profile →
  8. Analysis of acquired resistance mechanisms to osimertinib in patients with EGFR-mutated advanced non-small cell lung cancer from the AURA3 trial
    2023 95 citations Tony Mok, Yi‐Long Wu et al. profile →

Peers

Ji‐Youn Han
Isamu Okamoto Japan
Justin F. Gainor United States
Katsuyuki Hotta Japan
Jin Seok Ahn South Korea
Balázs Halmos United States
Rodryg Ramlau Poland
Jamie E. Chaft United States
Julien Mazières France
Sinéad Cuffe Ireland
Stefan Sleijfer Netherlands
Isamu Okamoto Japan
Ji‐Youn Han
Citations per year, relative to Ji‐Youn Han Ji‐Youn Han (= 1×) peers Isamu Okamoto

Countries citing papers authored by Ji‐Youn Han

Since Specialization
Citations

This map shows the geographic impact of Ji‐Youn Han's research. It shows the number of citations coming from papers published by authors working in each country. You can also color the map by specialization and compare the number of citations received by Ji‐Youn Han with the expected number of citations based on a country's size and research output (numbers larger than one mean the country cites Ji‐Youn Han more than expected).

Fields of papers citing papers by Ji‐Youn Han

Since Specialization
Physical SciencesHealth SciencesLife SciencesSocial Sciences

This network shows the impact of papers produced by Ji‐Youn Han. Nodes represent research fields, and links connect fields that are likely to share authors. Colored nodes show fields that tend to cite the papers produced by Ji‐Youn Han. The network helps show where Ji‐Youn Han may publish in the future.

Co-authorship network of co-authors of Ji‐Youn Han

This figure shows the co-authorship network connecting the top 25 collaborators of Ji‐Youn Han. A scholar is included among the top collaborators of Ji‐Youn Han based on the total number of citations received by their joint publications. Widths of edges represent the number of papers authors have co-authored together. Node borders signify the number of papers an author published with Ji‐Youn Han. Ji‐Youn Han is excluded from the visualization to improve readability, since they are connected to all nodes in the network.

All Works

20 of 20 papers shown
1.
Soo, Ross A., Urania Dafni, Ji‐Youn Han, et al.. (2024). ctDNA Dynamics and Mechanisms of Acquired Resistance in Patients Treated with Osimertinib with or without Bevacizumab from the Randomized Phase II ETOP-BOOSTER Trial. Clinical Cancer Research. 30(22). 5180–5191. 1 indexed citations
2.
3.
Burns, Timothy F., Konstantin H. Dragnev, Yutaka Fujiwara, et al.. (2024). Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.. Journal of Clinical Oncology. 42(16_suppl). 8510–8510. 22 indexed citations
4.
Fujiwara, Yutaka, Timothy F. Burns, Konstantin H. Dragnev, et al.. (2024). Efficacy and safety of olomorasib (LY3537982), a second-generation KRAS G12C inhibitor (G12Ci), in combination with pembrolizumab in patients with KRAS G12C-mutant advanced NSCLC.. Journal of Clinical Oncology. 42(23_suppl). 195–195. 2 indexed citations
5.
Lee, Jiyun, Hee Kyung Ahn, Sang‐We Kim, et al.. (2024). Real‐world treatment patterns and clinical outcomes in patients with stage III NSCLC in Korea: The KINDLE study. Cancer Medicine. 13(7). e7174–e7174. 1 indexed citations
6.
Lee, Youngjoo, Bo Song, Namhee Yu, et al.. (2024). Drug Response of Patient-Derived Lung Cancer Cells Predicts Clinical Outcomes of Targeted Therapy. Cancers. 16(4). 778–778. 3 indexed citations
7.
Okamoto, Isamu, Shoichi Kuyama, Nicolas Girard, et al.. (2024). TROPION-Lung07: Phase III study of Dato-DXd + pembrolizumab ± platinum-based chemotherapy as 1L therapy for advanced non-small-cell lung cancer. Future Oncology. 20(37). 2927–2936. 6 indexed citations
8.
Ju, Shinyeong, Sung‐Ho Goh, Byoung-Ha Yoon, et al.. (2024). Proteogenomic Characterization Reveals Estrogen Signaling as a Target for Never-Smoker Lung Adenocarcinoma Patients without EGFR or ALK Alterations. Cancer Research. 84(9). 1491–1503. 7 indexed citations
9.
Cho, Byoung Chul, Ji‐Youn Han, Ki Hyeong Lee, et al.. (2024). Lazertinib as a frontline treatment in patients with EGFR-mutated advanced non-small cell lung cancer: Long-term follow-up results from LASER201. Lung Cancer. 190. 107509–107509. 4 indexed citations
10.
Kim, Sunshin, et al.. (2023). Single targeting of MET in EGFR-mutated and MET-amplified non-small cell lung cancer. British Journal of Cancer. 128(12). 2186–2196. 5 indexed citations
11.
12.
Hartmaier, Ryan J., Aleksandra Markovets, Myung‐Ju Ahn, et al.. (2022). Osimertinib + Savolitinib to Overcome Acquired MET-Mediated Resistance in Epidermal Growth Factor Receptor–Mutated, MET -Amplified Non–Small Cell Lung Cancer: TATTON. Cancer Discovery. 13(1). 98–113. 95 indexed citations breakdown →
13.
Cho, Youngnam, Seog-Yun Park, Sunshin Kim, et al.. (2022). Early On-Treatment Prediction of the Mechanisms of Acquired Resistance to EGFR Tyrosine Kinase Inhibitors. Cancers. 14(6). 1512–1512. 3 indexed citations
14.
15.
Wolf, Jennifer Moriatis, Tobias R. Overbeck, Ji‐Youn Han, et al.. (2020). Capmatinib in patients with high-level MET-amplified advanced non-small cell lung cancer (NSCLC): results from the phase 2 GEOMETRY mono-1 study. Kölner Universitäts PublikationsServer (Universität zu Köln). 8 indexed citations
16.
Choi, Wonyoung, et al.. (2020). A nanowire-based liquid biopsy method using cerebrospinal fluid cell-free DNA for targeted management of leptomeningeal carcinomatosis. Journal of Cancer Research and Clinical Oncology. 147(1). 213–222. 13 indexed citations
17.
Lee, Youngjoo, Jungnam Joo, You Jin Lee, et al.. (2020). Randomized phase II study of platinum-based chemotherapy plus controlled diet with or without metformin in patients with advanced non-small cell lung cancer. Lung Cancer. 151. 8–15. 27 indexed citations
18.
Shin, Dong Hoon, et al.. (2018). Dual Targeting of ERBB2/ERBB3 for the Treatment of SLC3A2-NRG1–Mediated Lung Cancer. Molecular Cancer Therapeutics. 17(9). 2024–2033. 24 indexed citations
19.
Wu, Yi‐Long, Myung‐Ju Ahn, Marina Chiara Garassino, et al.. (2018). CNS Efficacy of Osimertinib in Patients With T790M-Positive Advanced Non–Small-Cell Lung Cancer: Data From a Randomized Phase III Trial (AURA3). Journal of Clinical Oncology. 36(26). 2702–2709. 349 indexed citations breakdown →
20.
Lee, Young Joo, Kyong‐Ah Yoon, Ji‐Youn Han, et al.. (2011). Circulating Cell-Free DNA in Plasma of Never Smokers with Advanced Lung Adenocarcinoma Receiving Gefitinib or Standard Chemotherapy as First-Line Therapy. Clinical Cancer Research. 17(15). 5179–5187. 64 indexed citations

Rankless uses publication and citation data sourced from OpenAlex, an open and comprehensive bibliographic database. While OpenAlex provides broad and valuable coverage of the global research landscape, it—like all bibliographic datasets—has inherent limitations. These include incomplete records, variations in author disambiguation, differences in journal indexing, and delays in data updates. As a result, some metrics and network relationships displayed in Rankless may not fully capture the entirety of a scholar's output or impact.

Explore authors with similar magnitude of impact

Breakdown of academic impact, for papers by Isamu Okamoto Breakdown of academic impact, for papers by Justin F. Gainor Breakdown of academic impact, for papers by Katsuyuki Hotta Breakdown of academic impact, for papers by Jin Seok Ahn Breakdown of academic impact, for papers by Balázs Halmos Breakdown of academic impact, for papers by Rodryg Ramlau Breakdown of academic impact, for papers by Jamie E. Chaft Breakdown of academic impact, for papers by Julien Mazières Breakdown of academic impact, for papers by Sinéad Cuffe Breakdown of academic impact, for papers by Stefan Sleijfer
Rankless by CCL
2026